mitotane has been researched along with Recrudescence in 9 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitotane proved to be an efficacious drug which in exceptional cases can be used without significant side effects in low dosage for the long-term treatment of hypothalamic-pituitary Cushing disease." | 5.30 | [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)]. ( Gerl, H; Knappe, G; Rohde, W; Ventz, M, 1997) |
| "Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy." | 2.49 | Update in adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M, 2013) |
| "UA induced remission of hypercortisolism in all patients, with sustained significant clinical improvement." | 1.42 | Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. ( Benoit, M; Caron, P; Chabre, O; Chaffanjon, P; Debillon, E; Lambert, B; Massoutier, M; Salenave, S; Tabarin, A; Velayoudom-Cephise, FL; Wagner, T; Young, J, 2015) |
| "Mitotane proved to be an efficacious drug which in exceptional cases can be used without significant side effects in low dosage for the long-term treatment of hypothalamic-pituitary Cushing disease." | 1.30 | [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)]. ( Gerl, H; Knappe, G; Rohde, W; Ventz, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fassnacht, M | 2 |
| Kroiss, M | 1 |
| Allolio, B | 2 |
| Kerkhofs, TM | 1 |
| Ettaieb, MH | 1 |
| Hermsen, IG | 1 |
| Haak, HR | 1 |
| Debillon, E | 1 |
| Velayoudom-Cephise, FL | 1 |
| Salenave, S | 1 |
| Caron, P | 1 |
| Chaffanjon, P | 1 |
| Wagner, T | 1 |
| Massoutier, M | 1 |
| Lambert, B | 1 |
| Benoit, M | 1 |
| Young, J | 1 |
| Tabarin, A | 1 |
| Chabre, O | 1 |
| Huang, H | 1 |
| Fojo, T | 1 |
| Terzolo, M | 1 |
| Ciccone, G | 1 |
| Berruti, A | 1 |
| Aron, DC | 1 |
| Findling, JW | 1 |
| Fitzgerald, PA | 1 |
| Forsham, PH | 1 |
| Wilson, CB | 1 |
| Tyrrell, JB | 1 |
| Knappe, G | 1 |
| Gerl, H | 1 |
| Ventz, M | 1 |
| Rohde, W | 1 |
| Luton, JP | 1 |
| Mahoudeau, JA | 1 |
| Bouchard, P | 1 |
| Thieblot, P | 1 |
| Hautecouverture, M | 1 |
| Simon, D | 1 |
| Laudat, MH | 1 |
| Touitou, Y | 1 |
| Bricaire, H | 1 |
| Sparagana, M | 1 |
| Ackerman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900] | 20 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence[NCT03723941] | Phase 3 | 240 participants (Anticipated) | Interventional | 2018-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitotane and Recrudescence
| Article | Year |
|---|---|
Update in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, | 2013 |
Developing treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2015 |
Cushing's syndrome: problems in management.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocorticotropic Hormone | 1982 |
6 other studies available for mitotane and Recrudescence
| Article | Year |
|---|---|
Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Adrenal Insufficiency; Adrenalectomy; Adrenocorticotropic Hormone; | 2015 |
Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
Topics: Adrenal Cortex Neoplasms; Antineoplastic Agents, Hormonal; Carcinoma; Chemotherapy, Adjuvant; Dose-R | 2008 |
Adjuvant mitotane for adrenocortical cancer--working through uncertainty.
Topics: Adrenal Cortex Neoplasms; Antineoplastic Agents, Hormonal; Carcinoma; Chemotherapy, Adjuvant; Dose-R | 2009 |
[The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
Topics: Adult; Chronic Disease; Combined Modality Therapy; Cushing Syndrome; Drug Evaluation; Female; Humans | 1997 |
Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.
Topics: 17-Hydroxycorticosteroids; Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; | 1979 |
Positive iodine-131 6 beta-iodomethyl-19-norcholesterol (NP-59) adrenal images can precede return of adrenocortical function after o,p' DDD treatment.
Topics: 19-Iodocholesterol; ACTH Syndrome, Ectopic; Adrenal Glands; Adult; Cholesterol; Humans; Iodine Radio | 1988 |